Ankylosing Spondylitis

Pain and fatigue levels remain high among patients with ankylosing spondylitis despite apparent disease control with biologic therapies, such as TNF inhibitors, according to a global survey published in the Journal of Clinical Rheumatology.

COVID-19 outcomes are worse among patients with inflammatory arthritis receiving glucocorticoids, but not in those receiving anticytokine therapy, according to data published in Arthritis & Rheumatology.

IL-17 inhibitors have recently demonstrated “quite effective” results in treating ankylosing spondylitis, according to a speaker at the 2020 Congress of Clinical Rheumatology-East.

Ankylosing spondylitis presents significant challenges in pain management and remains a controversial topic with limited data for efficacy.

Patients with complex, but not well-known diseases often find themselves at a loss for two important things: A voice and access to reliable information about their condition. Interestingly, the physicians who treat these patients often feel the same way.

A U.S. appeals court has ruled in favor of two patents for Amgen’s etanercept against the biosimilar etanercept-szzs from Novartis’ Sandoz, upholding a prior decision validating claims of patent infringement.

The time a person with ankylosing spondylitis spends undiagnosed can negatively impact quality of life.

While rheumatic diseases like ankylosing spondylitis confound clinicians, tumor necrosis factor inhibitors have shown consistent efficacy and safety to be a reliable tool for rheumatologists in this patient population.

Treatment with IL-17 inhibitors significantly increases response rates among patients with ankylosing spondylitis, but with an increased risk for non-severe infections, according to a meta-analysis published in Arthritis Research & Therapy.

The use of TNF inhibitors among patients with autoimmune disease may be associated with an increased risk for inflammatory central nervous system events, according to data published in JAMA Neurology.